Alligator Bioscience discovers and develops innovative antibody based immunotherapies for the treatment of cancer. Alligator Drug Discovery and Development span early research phases with lead identification up to proof of concept phase I/II clinical studies in cancer patients. In the discovery of novel antibody based drugs, Alligator uses its proprietary technology platforms FIND® and ALLIGATOR-GOLD®. FIND® (Fragment INduced Diversity) is an antibody optimization technology based on single-stranded DNA allowing generation of antibodies with significant clinical benefits. ALLIGATOR-GOLD® is a synthetic svFv library containing several billion distinct fully human antibodies. Alligator Bioscience AB was founded in 2001 and is a privately held company with around 200 shareholders, located at Medicon Village in Lund, Sweden.Alligators largest shareholders are the Copenhagen-based venture fund Sunstone Capital and DUBA AB, a fully-owned subsidiary of Investor AB, as well as some private individual investors.